3 No-Brainer Dividend Stocks to Buy in April [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Here's why they like AbbVie (NYSE: ABBV) Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) One of the most attractive dividends around Keith Speights (AbbVie): What's better than a high-dividend yield? I'd say a high-dividend yield combined with a growing dividend. That's exactly what you'll get with AbbVie. Let's start with the biopharmaceutical company's dividend yield of nearly 3.6%. High yields aren't unusual for AbbVie. The yield has topped 3% throughout most of its history. Few companies can compete with AbbVie on dividend growth. AbbVie has boosted its dividend payout by nearly 288% since separating from Abbott Labs in 2013. The big drugmaker is a Dividend King with 52 consecutive years of dividend increases (42 of those years were while it was part of Abbott). Can AbbVie keep this dividend growth going? I think so. The company expects to generate free cash flow of around $18 billion this year. It paid $10.5 billion in dividends in 2023. Sure, AbbVie's revenue
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Barclays PLC from $80.00 to $76.00. They now have an "equal weight" rating on the stock.MarketBeat
- Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Morgan Stanley from $80.00 to $78.00. They now have an "equal weight" rating on the stock.MarketBeat
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at TD Cowen from $90.00 to $85.00. They now have a "buy" rating on the stock.MarketBeat
GILD
Earnings
- 4/25/24 - Beat
GILD
Sec Filings
- 4/26/24 - Form 4
- 4/25/24 - Form 8-K
- 4/2/24 - Form 4
- GILD's page on the SEC website